Steven Bernstein and Nick Leschly

Nick Leschly beefs up his C-suite at 2sev­en­ty, hir­ing Bris­tol My­ers alum to lead clin­i­cal push for next-gen CAR-Ts

As Nick Leschly looks to ush­er in mul­ti­ple next-gen­er­a­tion CAR-Ts in­to the clin­ic, he has re­cruit­ed a sea­soned ex­ec to lead the push at 2sev­en­ty.

Steven Bern­stein, a for­mer head of in­te­grat­ed sci­ence, trans­la­tion­al med­i­cine at Bris­tol My­ers Squibb who most re­cent­ly served as Turn­stone Bi­o­log­ics’ chief trans­la­tion­al of­fi­cer, is com­ing on board as chief med­ical of­fi­cer.

“He brings both ex­pe­ri­ence as a treat­ing heme/on­col­o­gy physi­cian as well as ex­ten­sive trans­la­tion­al clin­i­cal ex­per­tise, in­clud­ing a deep knowl­edge of T-cell bi­ol­o­gy and im­munol­o­gy,” Leschly, who has trad­ed the ti­tle of chief blue­bird for chief kairos of­fi­cer, said in a state­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.